Evidence map›Paper›PMID 31932371›Full record

ArticleAntimicrobial agents and chemotherapy2020

New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection.

Oriana Simonetti, Guendalina Lucarini, Gianluca Morroni, Fiorenza Orlando, Raffaella Lazzarini, Antonio Zizzi, Lucia Brescini, Mauro Provinciali, Andrea Giacometti, Annamaria Offidani and 1 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Protegrin-1 and Analogues AgainstPharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Dalbavancin-resistantJAC-antimicrobial resistance · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. A Lead Target Molecule for Excisional Wound Healing: Trypthantrin Compound.Iranian journal of pharmaceutical research : IJPR · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. In Vitro Activity of Novel Lipopeptides against Triazole-ResistantJournal of fungi (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Novel dalbavancin-PLLA implant coating prevents hematogenousFrontiers in bioengineering and biotechnology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Oriana Simonetti *Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy o.simonetti@univpm.it.
Guendalina Lucarini *Histology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
Gianluca MorroniClinic of Infectious Diseases, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Fiorenza OrlandoExperimental Animal Models for Aging Unit, Scientific Technological Area, IRRCS INRCA, Ancona, Italy.
Raffaella LazzariniHistology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
Antonio ZizziPathologic Anatomy and Histopathology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Lucia BresciniHistology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
Mauro ProvincialiExperimental Animal Models for Aging Unit, Scientific Technological Area, IRRCS INRCA, Ancona, Italy.
Andrea GiacomettiClinic of Infectious Diseases, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Annamaria OffidaniClinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
Oscar CirioniClinic of Infectious Diseases, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Marche Polytechnic University · ITIstituto Nazionale di Riposo e Cura per Anziani · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dalbavancin is an effective antibiotic that is widely used to treat skin infection. Our aim was to determine the effect of dalbavancin administration on wound healing compared to that of vancomycin and to elucidate if epidermal growth factor receptor (EGFR), matrix metalloproteinase 1 (MMP-1), MMP-9, and vascular endothelial growth factor (VEGF) could be involved in its therapeutic mechanism. A mouse model of methicillin-resistant

Indexed as

AnimalsAnti-Bacterial AgentsBacterial LoadDisease Models, AnimalErbB ReceptorsMatrix Metalloproteinase 13Matrix Metalloproteinase 9MiceMice, Inbred BALB CStaphylococcal Skin InfectionsStaphylococcus aureusSurgical Wound InfectionTeicoplaninVancomycinVascular Endothelial Growth Factor AWound HealingAnti-Bacterial AgentsdalbavancinEGFR protein, mouseErbB ReceptorsMatrix Metalloproteinase 13Matrix Metalloproteinase 9Mmp13 protein, mouseMmp9 protein, mouseTeicoplaninVancomycinVascular Endothelial Growth Factor Avascular endothelial growth factor A, mousedalbavancinEGFRMMP-1MMP-9VEGFwound healing

Identifiers

PMID31932371
PMCPMC7179315
OpenAlexW3000277423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.